Octapharma IGIV Octagam Approved
This article was originally published in The Pink Sheet Daily
Executive Summary
Octapharma's IGIV product Octagam will be available in mid-June following FDA approval May 21
You may also be interested in...
Octapharma Octagam Efficacy Claims Are Unsubstantiated, FDA Warning Letter Says
Promotional materials disseminated by Octapharma at an American Academy of Allergy, Asthma & Immunology meeting also failed to reveal risks associated with use of the intravenous immune globulin.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.